Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Methylprednisolone for IBD Flares
NCT05587673Phase 1Completed
- Sponsor
- Stanford University
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylprednisolone in inflammatory bowel disease (IBD), sponsored by Stanford University. Primary endpoint: Number of patients with symptomatic, imaging or biopsy related improvement in their IBD symptoms at Week 6. Started Oct 2022; status: completed.
02
Drugs
methylprednisolone
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05587673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587673.